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Peter Goodfellow has recently been
appointed Senior Vice-President in
the Research and Development
division of the pharmaceutical
company SmithKline Beecham. Dr
Goodfellow’s most outstanding
contribution to research has been the
identification of genes that control
the development of maleness in
mammals. He has also had a
continued involvement in the
development of strategies currently
used in human molecular genetics,
and more recently has had a major
role in setting up a biotechnology
company. His combination of
commercial experience, scientific
expertise and a unique irreverence
should bring a new dimension to the
management of SmithKline
Beecham in the next few years.
Like many English lads, during his
youth Dr Goodfellow dreamt of
serving his country on the soccer
pitch. At the age of eighteen, he
realized that this was unlikely to
happen and was granted a place in the
microbiology course at the University
of Bristol. Having little idea of what
microbiology actually was, he read a
textbook on the train to his interview
and then proceeded to deliver a one
hour discourse on how microorganisms
could be used to extract gold. 
At Bristol, he discovered a natural
flair for understanding and thinking
within the framework of molecular
biology and consequently excelled at
his studies. At the end of his Honours
year he was advised that eukaryotic
genetics was likely to offer a more
promising future than prokaryotic,
and he accepted a postgraduate
position in Walter Bodmer’s laboratory
at the University of Oxford. 
Dr Goodfellow’s introduction to
human molecular genetics came with
his graduate project on the genetic
relationship of components of the
immune system. It was during this
time that he began using somatic
hybrid cell lines for gene mapping. In
1975 he received his PhD from
Oxford University and Julia
Goodfellow, his partner, became the
first woman to obtain a PhD from
England’s Open University. Together
they set off for Stanford University,
where Peter Goodfellow took up a
position with Hugh McDevitt to study
the serology of the mouse t locus. 
This was a difficult time for Dr
Goodfellow as his results went against
the established beliefs in the field. At
the end of his time at Stanford,
however, he had managed to learn
some developmental biology from
friends at UCSF and had also used his
knowledge of somatic cell hybridiza-
tion to introduce techniques for
monoclonal antibody production into
the San Francisco bay area. He had
also been ‘gobbed on’ by Sid Vicious
at the Sex Pistol’s final concert.
He returned to London to take
up a position at the Imperial Cancer
Research Fund’s laboratories, while
Julia Goodfellow took up a post in 
X-ray crystallography at Birkbeck
College. As a newcomer to the
ICRF, he had to fight for both space
and acceptance in what was, then,
quite a conservative establishment.
This was made plain when he heard
his lab — two slightly off-beat
research assistants and himself —
described as ‘a poof, a punk and a
weirdo’. 
While awaiting the arrival of
mouse strains from America to start
one of his projects, Dr Goodfellow
began using somatic cell hybrids to
map the chromosomal position of
genes encoding antigens that are
over-expressed in cancer cells. One
of these genes mapped close to the
proposed testis-determining factor
(TDF) gene, the locus on the Y
chromosome that initiates male
development. The Goodfellow lab
then began a number of positional
cloning strategies to isolate a
particular candidate for the TDF
gene but was beaten to it by David
Page’s group from the Massachusetts
Institute of Technology. 
Although Dr Goodfellow began
spending more time hidden under his
desk, reading poetry to his staff and
making them endless pots of
extraordinarily strong coffee, he was
not deterred. His group continued to
work on the molecular genetics of
mammalian sex determination, and in
1989 obtained results which suggested
that the gene isolated by Page’s group
was not the ‘master’ male-determining
gene. So the hunt for the TDF gene
began again. This time, a team led by
Andrew Sinclair, a postdoc in Dr
Goodfellow’s lab, successfully isolated
the correct gene and, in collaboration
with Robin Lovell-Badge’s group at
the National Institute for Medical
Research at Mill Hill, demonstrated
its male-determining activity. 
With the successful isolation of
the mammalian TDF gene came a
number of job offers — but an offer
from an American university was
withdrawn after Dr Goodfellow
presented his interview seminar using
the pointer as his sole visual aid, while
sitting cross-legged on a table at the
front of the auditorium. He
eventually accepted an offer to head
the Department of Genetics at the
University of Cambridge, England. 
Determined to make his mark
from the beginning, he immediately
began reading poetry to students,
762 Current Biology 1996, Vol 6 No 7
Peter Goodfellow
rebuilding a number of the
laboratories and centralizing many of
the facilities. His own lab expanded
considerably to include
mathematicians and computer
scientists as well as biologists. Dr
Goodfellow continued to develop his
work on gene mapping by generating
somatic hybrid cell lines which
contain only fragments of human
chromosomes. Along with Tony
Monaco, John Todd, Hans Lehrach
and others he helped set up the gene
mapping company Sequana, in San
Diego, California. Sequana has been
involved in a successful collaboration
to clone the Tubby gene and has
recently localized several candidate
genes involved with asthma.
Despite his success in numerous
fields of basic research, Dr
Goodfellow feels that the time is
now right to apply his unique
combination of scientific expertise
and commercial experience to the
practical development of
pharmaceutical products. While a
complicated three-way wager is on in
Cambridge regarding the length of
time his beard and pony-tail will
survive divided by the number of
days he will spend wearing a suit in
his new position at SmithKline
Beecham, Dr Goodfellow looks
forward to finding out whether  drugs
are even better than sex.
Biology in pictures
Something fishy
These days, individual chromosome
pairs can be distinguished not only
by their size and shape, but by colour
too. The image below shows a
pseudocoloured metaphase spread of
chromosomes from a normal human
male after multiplex fluorescent in
situ hybridization (M-FISH), a
technique that ‘paints’ each
chromosome  uniquely. 
One of the advantages of FISH
techniques is that several targets can
be visualized simultaneously using
probes labeled with different
fluorophores. Here, the hybridization
used a pool of 27 probes — 21 that
hybridize to individual
chromosomes, and specific probes for
the p and q (short and long) arms of
chromosomes 3, 5 and 11. 
The probes were generated by
chromosome microdissection
followed by amplification using the
polymerase chain reaction. Each
probe was then labeled uniquely,
using varying combinations of five
different fluorophores. Detection
filters were used that could
distinguish the emission spectra of
the individual probes, and each was
assigned a pseudocolour to generate
the image shown. 
This technique is more than just
decorative. It has been used to define
the karyotype of cell lines established
from human tumours, and proved
useful in identifying many types of
chromosomal rearrangement.
Fluorescence imaging of this type
should make possible completely
automatic karyotyping. 
For further details, see the paper
by M.R. Speicher, S.G. Ballard and
D.C. Ward, Nature Genet 1996,
12:368–375. The photograph was
kindly provided by Michael
Speicher, Department of Genetics,
Yale University School of Medicine,
333 Cedar Street, New Haven,
Connecticut 06510, USA. 
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